A federal vaccine advisory panel immediately gave its stamp of approval to Moderna’s mRNA influenza vaccine (mRNA-1010) for older adults.
By a unanimous vote, the Meals and Drug Administration’s (FDA’s) Vaccines and Associated Organic Merchandise Advisory Committee (VRBPAC) voted to suggest approval of the investigational vaccine, which can be marketed beneath the model title mFlusiva, for the prevention of flu in adults age 50 to 64.
Additionally they voted in help of accelerated approval in adults aged 65 and older. Moderna can be required to conduct a section 4, post-marketing research to show effectiveness within the older group.
The advice comes after a number of months of regulatory uncertainty over the vaccine. After initially agreeing to overview Moderna’s software for approval of the vaccine, the FDA modified course in February, saying that the section 3 trial for mRNA-1010 was not “enough and well-controlled” as a result of it used a standard-dose seasonal flu vaccine because the comparator vaccine.
Moderna mentioned that whereas the FDA had expressed a desire to make use of a high-dose flu vaccine as a comparator, company officers had agreed {that a} standard-dose flu vaccine was a suitable comparator.
The transfer raised issues about shifting regulatory requirements beneath the management of Well being and Human Companies Secretary Robert F. Kennedy Jr., who has been overtly essential of mRNA vaccines. In August 2025, Kennedy canceled $500 million in funding for 22 mRNA vaccine initiatives.
However every week later, the FDA reversed itself once more after Moderna proposed a revised regulatory strategy. The company agreed to overview the appliance for full approval in adults age 50 to 64 and accelerated approval for adults aged 65 and older, with an settlement to conduct a post-marketing research within the 65 and older group.
All 9 members voted in favor of approval
The VRBPAC overview centered on information from the section 3 trial, which concerned practically 41,000 adults 50 years and older in 11 nations through the 2024-25 flu season. The trial discovered mRNA-1010 offered considerably higher safety towards flu-like sickness than standard-dose pictures, with a relative vaccine efficacy of 27%. Immunogenicity information indicated efficacy within the 65 and over group.
VRBPAC members have been tasked with reviewing the information and voting on two questions: Do the advantages of mFlusiva outweigh the dangers for the prevention of flu in adults aged 50 to 64, and do the advantages outweigh the dangers in adults aged 65 and older? For the second query, members needed to resolve whether or not the immunogenicity outcomes from the section 3 trial offered an inexpensive foundation to foretell scientific profit.
Though there have been questions concerning the size of the trial (which lined just one flu season), the shortage of knowledge in immunocompromised and really frail older adults, and extra reactogenicity occasions (primarily fever) in those that acquired mRNA-1010, all 9 panel members voted sure on each questions.
“I do consider the information offered help that the advantages of the vaccine in each age teams outweigh the dangers,” mentioned VRBPAC member Flor Munoz-Rivas, MD, an knowledgeable in pediatric infectious illness at Baylor Faculty of Medication.
Moderna officers hailed the advice.
“We consider mRNA-1010 has the potential to supply an essential new choice for seasonal flu prevention and additional show the flexibility of our mRNA platform,” Moderna CEO Stephane Bancel, MBA, MSc, mentioned in an organization press launch. “We look ahead to persevering with to work with the FDA because it completes its overview.”
As a result of mRNA-1010 makes use of mRNA expertise as an alternative of conventional egg-based strategies, Moderna has recommended it could possibly be up to date extra rapidly to match circulating flu strains or a pandemic flu pressure. A number of VRBPAC members cited that as a possible profit.
That is one thing that appears prefer it has appreciable promise in various methods, so I believe it’s crucial that there was a cautious overview and an open dialogue.
“This specific platform provides thrilling ways in which we are able to truly transfer our vaccines to the longer term,” mentioned Hayley Gans, MD, of Stanford Medication.
In a media briefing after the vote, members of Georgetown College’s Professional Vaccine Evaluation Staff mentioned they have been joyful that the FDA modified course and agreed to overview the vaccine and that the VRBPAC members rigorously and totally weighed the dangers and advantages of the vaccine earlier than voting to suggest approval.
“That is one thing that appears prefer it has appreciable promise in various methods, so I believe it’s crucial that there was a cautious overview and an open dialogue,” mentioned Jesse Goodman, MD, MPH, a professor of drugs and infectious ailments at Georgetown and former director of the FDA’s Middle for Biologics Analysis and Analysis.
The advice now heads to the FDA, which has mentioned it’s going to make its determination by August 5.
